#$%^&*AU2020201826A120200402.pdf#####abstract Invasive breast cancer (IBC) patients with residual disease following neoadjuvant chemotherapy tave an anti-HER2 Type 1 T helper (Thl) cell immune deficit and a significant risk of recurrent disease. t has been shown that anti-HER2 CD4' T-cell responses incrementally decrease along the breast cancer :ontinuum - a robust response in healthy donors and patients with benign disease, a depressed response in >；atients with HER2' ductal carcinoma in situ, and a nearly absent response in patients with HER2* IBC. [his invention relates to a method of creating a microenvironment for culture expansion of T cells. The expanded T cells can be used for a variety of therapeutic and research purposes.1/15 * 0000 E (NJ4 CLC LUUCC 4= CD C CD C) U m~ C~4 C4 %(ie9OI1:/3IS) asuodsodAeiflwfl3 E (D'- N - N N(DI 00 IL 4 -J4 saplded OA113LGadjjaqtnN.
